Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 307

1.

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.

Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P, McClung M, Balske A, Thompson D, Daley M, Yates AJ.

N Engl J Med. 1998 Feb 19;338(8):485-92.

2.

Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial.

Ravn P, Bidstrup M, Wasnich RD, Davis JW, McClung MR, Balske A, Coupland C, Sahota O, Kaur A, Daley M, Cizza G.

Ann Intern Med. 1999 Dec 21;131(12):935-42.

PMID:
10610644
3.

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.

Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A.

Ann Intern Med. 2002 Dec 3;137(11):875-83.

PMID:
12458987
4.
5.

Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen.

Gallagher JC, Kable WT, Goldgar D.

Am J Med. 1991 Feb;90(2):171-8.

PMID:
1847582
6.

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M.

N Engl J Med. 1995 Nov 30;333(22):1437-43.

7.
8.

Changes in bone density and turnover after alendronate or estrogen withdrawal.

Wasnich RD, Bagger YZ, Hosking DJ, McClung MR, Wu M, Mantz AM, Yates JJ, Ross PD, Alexandersen P, Ravn P, Christiansen C, Santora AC 2nd; Early Postmenopausal Intervention Cohort Study Group..

Menopause. 2004 Nov-Dec;11(6 Pt 1):622-30.

PMID:
15545790
9.

Effect of daily hormone therapy and alendronate use on bone mineral density in postmenopausal women.

Davas I, Altintas A, Yoldemir T, Varolan A, Yazgan A, Baksu B.

Fertil Steril. 2003 Sep;80(3):536-40.

PMID:
12969694
10.

Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.

Devogelaer JP, Broll H, Correa-Rotter R, Cumming DC, De Deuxchaisnes CN, Geusens P, Hosking D, Jaeger P, Kaufman JM, Leite M, Leon J, Liberman U, Menkes CJ, Meunier PJ, Reid I, Rodriguez J, Romanowicz A, Seeman E, Vermeulen A, Hirsch LJ, Lombardi A, Plezia K, Santora AC, Yates AJ, Yuan W.

Bone. 1996 Feb;18(2):141-50. Erratum in: Bone 1996 Jul;19(1):78.

PMID:
8833208
11.

Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group.

McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS, Fuleihan G el-H, Reda C, Yates AJ, Ravn P.

Ann Intern Med. 1998 Feb 15;128(4):253-61.

PMID:
9471927
12.

The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis.

Yan Y, Wang W, Zhu H, Li M, Liu J, Luo B, Xie H, Zhang G, Li F.

J Bone Miner Metab. 2009;27(4):471-8. doi: 10.1007/s00774-009-0057-7.

PMID:
19343272
14.

Alveolar and postcranial bone density in postmenopausal women receiving hormone/estrogen replacement therapy: a randomized, double-blind, placebo-controlled trial.

Civitelli R, Pilgram TK, Dotson M, Muckerman J, Lewandowski N, Armamento-Villareal R, Yokoyama-Crothers N, Kardaris EE, Hauser J, Cohen S, Hildebolt CF.

Arch Intern Med. 2002 Jun 24;162(12):1409-15. Erratum in: Arch Intern Med. 2004 Jan 12;164(1):96.

PMID:
12076241
15.
16.
17.

A 3-year study of prevention of postmenopausal bone loss: conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone.

Thiébaud D, Bigler JM, Renteria S, Pache T, Welti HJ, Landry M, Burckhardt P.

Climacteric. 1998 Sep;1(3):202-10.

PMID:
11907945
18.

Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.

Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.

Bone. 2006 Dec;39(6):1268-75.

PMID:
16884968
19.

Prevention of postmenopausal bone loss by low and conventional doses of calcitriol or conjugated equine estrogen.

Ongphiphadhanakul B, Piaseu N, Tung SS, Chailurkit L, Rajatanavin R.

Maturitas. 2000 Feb 15;34(2):179-84.

PMID:
10714913
20.

HRT and exercise: effects on bone density, muscle strength and lipid metabolism. A placebo controlled 2-year prospective trial on two estrogen-progestin regimens in healthy postmenopausal women.

Heikkinen J, Kyllönen E, Kurttila-Matero E, Wilén-Rosenqvist G, Lankinen KS, Rita H, Väänänen HK.

Maturitas. 1997 Mar;26(2):139-49.

PMID:
9089564

Supplemental Content

Support Center